U.S. FDA Approves Pfizer’s Xeljanz (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis

NEW YORK–(BUSINESS WIRE) September 28, 2020 — Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved Xeljanz® (tofacitinib) for the treatment of children and adolescents 2 years

Fewer U.S. Doctor Are Facing Burnout

FRIDAY, Feb. 22, 2019 — For decades, U.S. doctors have battled the long hours and demanding schedules that often lead to “burnout.” But a new study brings welcome news, showing a slight decline in the